How Lowered EBITDA Guidance Will Impact Hims & Hers Stock Investors
- Hims & Hers Health reported Q3 2026 revenue of US$890.37 million and a net loss of US$33.04 million, reduced its 2026 adjusted EBITDA guidance, and highlighted softer subscriber trends due to delayed U.S. weight loss marketing and increased investment in the U.K. and Germany.
- The firm is adding high profile growth initiatives such as the Eli Lilly obesity drug agreement, a new Peptides+ product category, and Andrew Huberman’s appointment to the board and a marketing advisory role, at the same time that near term profitability and customer additions are under pressure.
- This article examines how Hims & Hers Health's multi-year growth narrative aligns with weaker Q3 profitability and delayed weight loss momentum.
Hims & Hers Health Investment Narrative Recap
To stay invested in Hims & Hers Health, you need to believe in the multi category, multi country platform idea that Deep_Insights, an investor in the Simply Wall St Community, describes as a long term healthcare ecosystem rather than a single weight loss story. The near term pressure sits around weaker Q3 profitability, guidance reset and softer subscriber trends, while weight loss marketing in the US is delayed.
The key near term catalyst is a return to healthier subscriber additions once US and international marketing, pricing and new treatments line up against the Eli Lilly and Novo Nordisk agreements. The biggest risk right now is execution, meaning that higher spend in the U.K. and Germany and new categories could add complexity and cost faster than it supports a move toward profitability.
The agreement with Eli Lilly on Zepbound and Foundayo is the clearest link between the current setback and future opportunity. It keeps Hims & Hers Health connected to branded GLP 1 demand while the platform works through a period of reduced US weight loss marketing and weaker short term EBITDA guidance. Patients can complete the full journey inside the Hims & Hers experience, which matters for future cross sell potential.
For you as a shareholder, that Lilly partnership sits alongside the earlier Novo Nordisk relationship as a core catalyst, because it anchors the weight loss offering inside a broader subscription model that Deep_Insights sees as the real thesis. The risk is that high self pay price points, regulatory scrutiny or operational complexity around GLP 1 distribution could limit how much of that demand converts into sustainable, profitable memberships on the platform.
Deep_Insights calculates a fair value of US$171.19 per Hims & Hers Health share by applying a 60x earnings multiple to a scenario in which revenue grows 33.0% per year and the business eventually earns a 9.0% net profit margin.
Uncover how Hims & Hers Health's fair value indicates a 768% potential upside to its current price that may not last much longer.
Exploring Other Perspectives
For Hims & Hers Health, the sharpest contrast comes from bearish analysts who focus on regulatory and payments scrutiny as the real swing factor, rather than new board firepower from Andrew Huberman. That group was penciling in roughly 16.7% annual revenue growth to about US$4.1b and earnings of US$163.7 million by 2029, so the latest leadership and guidance news may push those expectations in either direction.
Explore 14 other Hims & Hers Health fair value estimates, including one that suggests it could be worth just $28.31!
The Verdict Is Yours
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Hims & Hers Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Hims & Hers Health. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Hims & Hers Health's overall financial health at a glance.
Looking For More Ideas Beyond Hims & Hers Health?
If the Hims & Hers Health story has you rethinking where growth, quality and risk really line up, it can help to scan a wider field of opportunities using the Simply Wall St Screener.
- For investors who want quality and value working together, consider reviewing a 32 high quality undervalued stocks that combine strong fundamentals with more modest pricing.
- If capital protection is near the top of your checklist, you might prefer a 31 resilient stocks with low risk scores that screen for sturdier balance sheets and steadier returns profiles.
- When you are hunting for future leaders before they become widely followed, a 20 high quality undiscovered gems can surface under-the-radar businesses with resilient financials.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com